StemCell Therapy

Prevent Blindness Declares April as Women's Eye Health and Safety Month to Educate Public on Ways to Save Sight

CHICAGO, March 26, 2020 /PRNewswire-PRWeb/ -- Because women have higher rates of eye diseases and eye conditions than men, Prevent Blindness, the nation's oldest non-profit eye health organization, has designated April as Women's Eye Health and Safety Month. The group provides free information to the public on various eye health topics, including vision issues, possible changes in vision during pregnancy, cosmetic safety and more.

Women have a higher prevalence of many of the major vision problems, including:

The National Eye Institute states that 26 percent more women aged 12 and older have uncorrected visual impairment due to refractive error compared with men aged 12 and older. And, 14 percent more women aged 40 and older have refractive errors compared with men aged 40 and older. Additionally, women are also more likely to have autoimmune conditions, which often come with visual side effects.

According to the American Academy of Ophthalmology, for women, fluctuating hormone levels of estrogen and progesterone can affect the eye's oil glands, which can lead to dryness. Estrogen can also make the cornea less stiff with more elasticity, which can affect how light travels into the eye. The dryness and the change in refraction can cause blurry vision and can also make wearing contact lenses difficult.

Pregnancy brings an increase in hormones that may cause changes in vision. Women with pre-existing eye conditions, like glaucoma, high blood pressure or diabetes, need to alert their eye doctor that they are pregnant (or planning to become pregnant).

Lastly, women often make the majority of their family's health care decisions and are often responsible as caregivers for the health care choices of their children, partners, spouse, and aging parents. It is important to remind women to make their own vision and eye health a priority to prevent unnecessary vision loss in the future.

Prevent Blindness recommends steps that should be taken to protect vision and eye health, including:

OCuSOFT Inc., a privately-held eye and skin care company dedicated to innovation in eyelid hygiene and ocular health, is partnering once again with Prevent Blindness in support of April's Women's Eye Health and Safety Month.

"Today, obviously there are significant challenges in maintaining overall health," said Jeff Todd, president and CEO of Prevent Blindness. "We want to remind women of all ages that there are many ways to protect the gift of sight today so that it can be enjoyed for many years to come."

For more information on women's eye health, including fact sheets on eye diseases and eye protection, please visit https://www.preventblindness.org/see-jane-see or call (800) 331-2020. Prevent Blindness offers a free listing of financial assistance services in English and Spanish at: https://www.preventblindness.org/vision-care-financial-assistance-information.

About Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

SOURCE Prevent Blindness

Read the original here:
Prevent Blindness Urges Women to Make Their Vision Health a Priority Today to Help Protect it for the Future - Yahoo Finance

The Fatal Eggs is a parable of bureaucratic bungling and drastic countermeasures

Mar 25th 2020

Editors note: The Economist is making some of its most important coverage of the covid-19 pandemic freely available to readers of The Economist Today, our daily newsletter. To receive it, register here. For more coverage, see our coronavirus hub

The Fatal Eggs. By Mikhail Bulgakov. Translated by Hugh Aplin.Hesperus Press; 112 pages; 6.99.

WHEN PROFESSOR Vladimir Persikovs wife runs off with an opera singer, she leaves him a note. An unbearable shudder of revulsion is aroused in me by your frogs, she tells him. In The Fatal Eggs, a little-known novella by Mikhail Bulgakov, a pestilence spawned by the professors zoological research threatens not just his marriage, but civilisation itself.

The scourge in the storypublished in 1925 and set three years lateris not a disease, exactly. In their imagination of epidemics, novels such as Mary Shelleys The Last Man, The Plague by Albert Camus or Jos Saramagos haunting Blindness might seem more apposite in the time of covid-19. Nor is this biting tale Bulgakovs finest work (that is his satirical fantasia, The Master and Margarita). But as a parable of bureaucratic bungling, avoidable disaster and drastic countermeasures, it is horribly relevant.

In his laboratory in Moscow, Persikov discovers a ray of life that makes amoebae and tadpoles reproduce at speed. Thrilled, he orders extra kit from Germany and exotic eggs from across the Atlantic (like the virus, this is a globalised affair). Foreign powers covet the new technology, but the Soviet state requisitions it to help kick-start poultry production. The apparatchik in charge of the state farm, Alexander Faight, was once a flautist in Odessa; he is carrying his instrument when he encounters a giant serpent, which he tries to pacify with a waltz from Eugene Onegin. He fails, and the beast eats his wife.

The Russian author takes digs at the church, heedless carousers in the streets, blinkered scientistsand, naturally, at the Bolsheviks. But his depiction of blas, incompetent officialdom resonates across the ages and all forms of government. Honest to God, itll work out, Faight says blithely of the poultry plan, like a president recommending an unproven drug. Disaster ensues because the authorities botch their deliveries, sending the hens eggs meant for the farm to Persikov, and his exotic specimens to the farm. Then, after the creatures hatch, the first, all-too familiar response is disbelief and denial. Faight stammers a report to two security agents; one thinks he is hallucinating, the other that a circus animal might have escaped. A newspaper editor dismisses an urgent telegram as a drunkards raving.

Before long, though, everyone goes berserk. Martial law is declared in Moscow amid a flood of refugees. Like quarantined Europeans applauding ambulances from their balconies, cowering citizens take to the pavements to salute the cavalrymen on their way to interspecies battle, and the marching gas squadrons with breathing tubes over their shoulders and with cylinders on straps behind their backs. Artillery units bombard forests; aeroplanes spray poison. Civilian casualties mount. And, following a perennial instinct, vigilantes hunt for someone to blame.

In the end, the weather intervenes, as some hope it might today. An unseasonable summer frost kills the serpents and freezes the eggs, and a year after the trouble arose, it is all over. Moscow, Bulgakov writes encouragingly, again began to dance, to burn and to spin with lights.

Dig deeper:For our latest coverage of the covid-19 pandemic, register for The Economist Today, our daily newsletter, or visit our coronavirus hub

This article appeared in the Books and arts section of the print edition under the headline "The yolk of fate"

See the original post here:
Bulgakovs biting vision of an avoidable plague - The Economist

Elmiron, a medication used to treat bladder conditions, may be associated with a rare eye condition called pigmentary maculopathy, according to recent scientific reports. Pigmentary maculopathy reportedly occurs after long-term Elmiron treatment.Ring of Fires Farron Cousins discusses this with Scott Hardy, the President of Top Class Actions.

Transcript:

*This transcript was generated by a third-party transcription software company, so please excuse any typos.

Farron Cousins:A popular bladder medication called Elmiron has now been linked to very serious side effects that affect a patients eyes and their vision. Joining me now to talk about this investigation is Scott Hardy with top class actions and Scott, unfortunately this is a very common story. We see this with a lot of pharmaceuticals all the time. One of the biggest areas of, of, of legal practice in the country today is bad pharmaceuticals and it looks like we may have another one on our hands. So tell us whats happening here.

Scott Hardy:Sure. So weve actually reported on Elmiron in the past, and its connection to possible macular degeneration, but whats really peaking attorneys interest right now is the connection to pigmentary macula, maculopathy. And so its similar to macular degeneration, but it can also result in blindness for people. A very good friend of top class actions was just talking to me last night and she said, shes got this bladder condition. And she said, you know, Scott, I wanted to take Elmiron because the bladder condition is so painful. Its, its terrible. But knowing about this side effect, I dont want to go blind and there are support groups of people out there that take Elmiron and that have said, yeah, Im starting to see some of these symptoms.

And so thats what these attorneys are going after because people havent been warned that if they take Elmiron for this bladder issue that they could go blind and its, it hasnt been populated out there and this is the only drug thats affective for this specific condition. So it puts these folks in a very tough position of, do I, do I suffer the pain and the discomfort of having this, this bladder issue? Or do I roll the dice and take Elmiron for some relief and hope that I dont have permanent vision problems after taking it?

Farron Cousins:See, thats a really interesting point there because usually what we see in the cases of these pharmaceuticals, the lawsuits, is itll be a relatively new drug thatll come out and the pharmaceutical companies go out there and tell doctors, hey, our drug is way more better than something thats been on the market for 20 years. So please start prescribing this and then the side effects pop up. The patient has to switch to the other. But in this one, as you say, there is no other one. So were not looking at necessarily the same scenario that we typically see with these pharmaceutical cases where they push something they know is dangerous as better than something that is not.

So this is a very tough position I guess for, for these patients to be in. And, you know, you mentioned somebody you know has a bladder condition, a family member of mine has one and these are exceedingly painful for people. They, they want relief, they need relief and its going to put them in the position, well do I want this pain, this constant pain to stop and possibly go blind or do I just live with pain and not risk it? Thats a horrible choice for anyone to have to make.

Scott Hardy:It really is and the problem is that people dont know if they will be impacted by it and they dont know if they can start taking Elmiron and get some relief for their bladder issue and then start experiencing partial blindness, blurred vision, other problems, and then go, okay well Im going to stop. Because unfortunately some of these medical issues, once that ball starts rolling down that hill, there is no stopping it and so its unclear, you know, Ive had friends with MS that were taking a specific drug and then as soon as they tested positive for a certain condition, they stopped taking it. Because it could cause death, once they tested positive. For this one, they dont know. You know, if youre taking Elmiron and then all of a sudden you start having blurry vision, you start having vision issues and you stop taking the drug, it might be too late.

And thats what we, you know, Id love for the makers of Elmiron to come out and say, hey, heres a strategy. Because thats what they did with this MS drug is they said, hey, our drug works and so were going to test you every six months and as soon as you hit positive for this specific condition, well tell you if you continue taking this drug and you have this condition, it can kill you. What do you want to do? Elmiron hopefully will have a similar strategy to come out with and say, well run tests, use our drug, get that relief that you want. But heres some tests and if you start suffering these problems, then well pull you off it, then well figure out a new treatment solution.

Farron Cousins:Absolutely. So lets hope that that happens. As of right now, obviously this investigation is still ongoing and, you know, if it yields the results that its already been yielding, we can expect, you know, pretty significant lawsuits in the near future. So folks, if youre on this drug, if you know anybody on this drug, please follow the link in the description of this video. Head on over to top class actions and if you havent already done so, please do subscribe to their weekly newsletter. Scott Hardy with top class actions, always a pleasure. Thank you.

Scott Hardy:Youre welcome. Thanks for your time.

See the original post here:
Bladder Medication Linked To Dangerous Eye Problems - The Ring of Fire Network - The Ring of Fire Network

object(stdClass)#31166 (59) { ["id"]=> string(4) "5757" ["title"]=> string(52) "13 Things To Consider Before Selling Products Online" ["alias"]=> string(52) "13-things-to-consider-before-selling-products-online" ["introtext"]=> string(153) "

If you're thinking about selling products online but you're unsure where to begin then don't worry, you have definitely come to the right place.

Whether you've been running your business for years or you've only just started, you need to be sure you're as prepared as you can be when it comes to selling your products online. Luckily, there are lots of ways in which you can do exactly that. From working out which products you're going to sell to finding out a way to direct traffic to your store, you need to be sure you're doing all that you can to prepare for your launch in advance. Whilst it may be overwhelming at first, you'll be thankful when your business is a huge success. With that in mind, here are 13 things to consider before selling your products online:

One of the first things you need to do when it comes to selling your products is to put together a business plan. Whether youve already started working on one or youre yet to give it a go, having a business plan in place in the best way to ensure your business is going to get off to a strong start. It will feature your mission statement, your goals and all of the steps youre going to need to take in order to run your business successfully.

Although it can take some time to put together, having a business plan is essential for those that want to succeed. For some tips and tricks when it comes to putting together a business plan, you can visit this site here.

While youre putting together your business plan, you also need to think about the products youre going to sell. Whether youre selling your full product line online or youre just choosing a select few products, having a clear idea of what you want to list online will make all of your other decisions much easier. If youre unsure what you should be selling online, you may want to take a look at what your competitors are doing and what is performing well for them. It may be that you launch a couple of products, to begin with, and then build on your range.

When youre thinking of your products, you need to consider whether or not youre going to be buying them yourself or getting them from a supplier. Although both are great options, you need to think about your business model before you started selling things online. Have you always created your own products? Do you make enough profit margin? For a guide to making your own products for your business, you can visit this site here.

Another important thing to consider when it comes to your products is how much stock youre going to need at once. If youre a small business that only gets one or two orders a week, chances are youre not going to need to keep high levels of stock. If youre expecting lots of orders, however, youre going to need to ensure you have the stock levels that are needed to fulfil the orders. If you notice youre getting busier and busier each week, you may want to consider increasing your stock in small increments.

If you have to invest a lot into your stock before it sells, its best to start with small numbers at first.

Once you have started to think about the products youre going to sell and the quantity of stock youre going to need to think about where youre going to be selling them. Whether youre using social media as your sole platform or youre using sites like Etsy or eBay, its important you know which platform your target audience is most likely going to be using. If youre unsure, you may want to trial a couple of different platforms before you find what is right for you. For advice when it comes to choosing the right platform to sell your products, you can visit this site here.

Another great way to sell your products online is to build your own website, which is what most online sellers should be aiming to do as their business starts to grow. If youre going to be setting up your website from the start of your launch, you need to be sure youre doing all that you can to make it a success. This means hiring a designer and web developer, putting all your efforts into writing the web copy and ensuring that it works from a user perspective. The more time you put into your website, the better.

If youre worried about creating a website, there are lots of people that you can outsource the work to. Not only will this help free up your time but it will also ensure that your website is fully functional from the get-go.

Once you have built your website or started listing your products online, you need to think about how youre going to be driving traffic to your website. From focussing on your SEO to working with a paid ads specialist, there are lots of ways to get people to click through to your site. Although it may not happen right away, after a little bit of hard work youll soon start to see your numbers grow. Patience is key when it comes to traffic.

Another great way to direct traffic to your site and to grow your brand is to use social media to promote your products. Again, this is not something that will happen instantly but if youre consistent in your message it will come. Whether youre using Instagram to share photos of your products or youre using Facebook to go live and show a behind the scenes look at running a business, the more followers you have the more chance you have of turning them into paying customers.

When it comes to followers, you need to ensure theyre all within your target audience if you want a high chance of converting them.

If youre struggling to grow your brand and direct traffic to your site, working with influencers and bloggers is a great idea. Working with influencers who have a similar target audience to you will allow you to get your products in front of people who may be interested. Although it will cost you, its proven to be super effective.

Another important thing to consider when it comes to selling your products online is how youre going to be shipping your products once they start to sell. Whether youre using a shipping company or youre heading to the post office on your own, you need to choose the method that is easiest for you. In most cases, it will come down to the time and cost that you have to invest. For more information when it comes to shipping, you can visit this site here.

Speaking of shipping, you also need to think about whether or not youre going to be charging for delivery. Although some companies choose to offer free delivery over a certain spend, often not possible for those that are running small businesses from their home. If you do want to charge free delivery, you need to ensure your prices reflect that.

Another important thing to consider is whether or not you need to put together a refund and returns policy. Although you dont necessarily want to think about people returning your products and asking for refunds, having a policy in place will make it much easier should this happen. If you can, try to include this policy on your website.

If you need help when it comes to putting together a refund and returns policy, you can visit this site here.

Finally, you need to think about whether or not you have a contingency plan in place. Although you may never need to use it, knowing what youre going to do if your business is not successful is important as it will allow you to prepare in advance. After all, you never know what could happen in the world of business.

Are you thinking of starting an online business selling products? What can you do to ensure your business is a success from the start? How will you be selling your products? Did we miss anything? Let me know your thoughts and ideas in the comments section below.

More here:
Effect of Banner Blindness on Design - BBN Times

Pastor Terry Goerz,Redeemer Lutheran Church

Jesus healed a man who was born blind. The church officials of the day refused to believe that Jesus could have done this, since in their eyes Jesus was a sinner. He was healing on the Sabbath, the holy day, when no work was to be done.

The blind man testified he was born blind and Jesus put some mud on his eyes, told him to go wash, and he could see.

They refused to believe. They called his parents who testified that he was born blind and now he could see, but they did not know how.

They called the blind man again who again testified that Jesus had restored his sight. They still refused to believe, Jesus was a sinner, and God does not use sinners to heal.

The man born blind not only had his physical sight restored, but he had his spiritual sight restored as he worshiped Jesus as the Son of Man, that is the long promised Messiah who was to save the world.

Jesus concluded this account saying in John 9:39, For judgment I have come into this world, so that the blind will see and those who see will become blind.

When we read this account from scripture we may feel what dummies. Couldnt they see the obvious? Sadly, this same blindness is all around us today. God creates us as spiritual beings, knit together in the womb, yet multitudes of babies are murdered in the womb.

It is now legally possible to take your own life, or anothers, through the euthanasia legislation. Homosexuality, described as an abomination to God, is now celebrated as an alternative life style. Marriage, which is described in scripture as the lifelong union of one man and one woman, is ignored with same sex marriage becoming common.

It seems our society today suffers from the same blindness that the church officials of Jesuss day suffered from. We think, as a society, we are so advanced, so smart, so enlightened. Yet the word of God seems to be screaming what dummies.

The real problem, though, is not connected to mankinds natural intelligence. As a result of the fall of man in the garden of Eden we are all born in sin and conceived in iniquity. We are naturally alienated enemies of God and destined for an eternity separated from God in a torturous place called hell; unless we have our spiritual eyes opened. Without God working in our lives, mankind cannot see and understand what is obvious.

As Jesus said earlier, For judgment I have come into this world, so that the blind will see and those who see will become blind.

Paul tells us the same thing in 1 Corinthians 1:18,19 for the message of the cross is foolishness to those who are perishing, but to us who are being saved it is the power of God. For it is written, will destroy the wisdom of the wise; the intelligence of the intelligent I will frustrate.

Fortunately for mankind we have a God who is full of mercy and grace. It is His desire that all mankind be saved and come to a knowledge of the truth. This is the message of reconciliation that has been committed to all Christians.

2 Corinthians 5: 1921: That God was reconciling the world to Himself in Christ, not counting mens sins against them. And He has committed to us the message of reconciliation. We are therefore Christs ambassadors, as though God were making His appeal through us. We implore you on Christs behalf: Be reconciled to God. God made Him who had no sin to be sin for us, so that in Him we might become the righteousness of God.

While there may be some value in rallying and lobbying against the blindness that is so obvious in our society, the real answer is to apply the balm that opens their eyes. God made Jesus to be sin for us. Jesus has paid the penalty for the sin of the whole world, past, present and future.

We who serve our Lord should be acting as Christs ambassadors and telling all those around us that God wants to be reconciled to them, that forgiveness and life eternal are a free gift available to all who will believe.

God will use that message in those whom He has called and chosen to open their eyes to the truth. One by one God will use us as He snatches the lost from the fire.

Blessings!

Link:
Inspiration - We are all Christ's ambassadors | - South Peace News

Can the Coronavirus be the key to getting Bill Cosby out of the slammer? His lawyers hope so.

As per Page Six, Cosbys legal team is filing a motion to get him released from his Pennsylvania jail and put on house arrest amid reports that at least one prison officer has tested positive for COVID-19.

At his age, Cosby is at a greater risk of having serious complications if he were to contract the Coronavirus. Not to mention the close quarters in prison.

His lawyers say he is not a threat to the public if hes allowed to serve his time from home due to his advanced age and blindness. He would wear an ankle monitor and his wife would supposedly take care of him.

Will the plea work? We will have to wait and see. Considering his Pennsylvania mansion is 9,000-square-feet, as Page Six notes, he can easily practice social distancing.

Related:Celebrity Inmate Bill Cosby Says He'd Rather Do A Decade In Prison Than Show Remorse

Another celebrity-turned-criminal dealing with COVID-19 is Harvey Weinstein. Hehas tested positive for the virus, as we reported on The Things. Will Weinstein be handed a get out of jail free card too, so he doesnt spread it around?

Cosby may even push for Weinstein to be given special treatment. Cosbys publicist called Weinsteins conviction a sad day for the American judicial system, as NBC News reported.

Two peas in a pod? At least theyre not in the same prison.

Next:More Trouble For Harvey Weinstein... He Tests Positive For Coronavirus!

Mason Disick Takes To Social Media And Spills Info About Kylie Jenner

See the rest here:
Free Cosby... From Coronavirus | TheThings - TheThings

in Lifestyle 27-03-2020 01:00:00 0 Comments

If you're lucky enough to have your own garden, there's lots of ways you and your family could enjoy it - and connect with nature and benefit from a wellbeing boost in the process.

With social distancing at the height of the agenda at present, you might need to make sure you keep a safe distance from neighbours, so be sensible and follow the all-important guidelines. But gardens can bolster wellbeing for both children and adults, says gardening writer, presenter and horticultural influencer Ellen Mary.

Mary, who specialises in gardening for wellbeing, has just launched a 30 Moments In Nature challenge on her website, featuring activities to help people reconnect with nature.

"We all lead such busy lives, with everyday stresses of work, school and digital life, that 'nature deficit disorder' and even 'plant blindness' has become all too real," she says.

"There is nature everywhere, and spotting it, even in the most unlikely places, can give a much better understanding of how we are all connected - to nature, not our phones."

Here, Mary offers top tips on how you and your children can reconnect with nature in your own garden...

1. Garden tracing

This is an activity many of us took part in at school as a child and it's still really good fun, no matter what age we are. Children can learn about plants and trees in their garden, identify them and be outside away from computers and mobile phones. Studies have shown that walking among trees reduces levels of cortisol and can even boost the immune system.

Activity: Take a walk in your garden with some paper and a crayon. Trace the bark of a tree, if you have one, and a fallen leaf to stick on the paper by your tracing. Look closely at the tree, identify it, touch the bark and the leaves. Back inside, put it on your fridge. Each time you look at your tracing, remember how you felt in the garden, the smells and the air on your face.

2. Walk barefoot

Walking barefoot brings us into direct contact with the planet and allows us to absorb the natural energy the earth provides. This is known as 'earthing' and it's said to have a host of benefits. Great on a warm morning in the garden.

Activity: Get your socks off! Put your shoes aside. Feel liberated by walking outside on the lawn or a soft outdoor surface with bare feet. Feel the natural negative charge from the earth being absorbed through the soles of your feet. Allow it to happen, accept it. Breathe deeply and relax.

3. Spot a star constellation

When we are busy looking down at phones and laptops, it's easy to forget to look up. By looking up at the night sky not only is it a hub of fascination and awe but it's also a relaxing activity before bedtime. Finding shapes in the moon and trying to spot star constellations can be a lovely way to switch off before a good night's sleep.

Activity: Did you ever stare at the stars as a child and wonder what they are? Glistening in the sky, light years away. It's really good fun identifying star constellations but if you can't work out where Orion is, make your own shapes in the sky like a dot-to-dot drawing.

4. Sow some seeds

Sowing seeds is now only a great way to grow your own food, but also for children to understand where their food comes from. Great seeds to try with children are sunflowers, nasturtiums and microgreens, which grow really quickly.

Activity: Be mindful and sow some seeds. Before you do, feel the seeds in your hand. What is the texture, shape, size? Look close at the detail - does each seed differ? Smell them and if they are edible, taste them. Be marvelled at the way those tiny seeds become big fruits, vegetables or flowers.

5. See life beneath

Picking up a large stone from your garden, your children will be able to marvel at the life beneath. They'll be fascinated by the woodlice, ants, worms and beetles. We forget that inner child as we grow up and life takes over.

Activity: Revisit those memorable moments with your children, lifting a stone in your garden and encouraging the children to stay inquisitive and keep looking.

Original post:
Fun ways for kids to reconnect in the garden - The Portugal News

Monday marked the turning. There appeared a line that we all stepped over together into this odd, unsettled twilight land we now find ourselves in.

On Friday thousands still gathered at Bondi beach. But a friend who was there said the vibe, which couldnt be captured by the pictures (themselves now viral), was more complex. There was this instinct to come together one last time, to seize the dwindling moment, he told me. It was less wilful blindness, he said, and more paradoxically a life-affirming impulse in the face of the terrible known unknown that was coming next.

By Sunday, Bondis brief Weimar Republic moment was over. The beaches were fenced shut. We all knew now, if we didnt know it then, that our lives would enter a new, much darker phase, unlike anything most of us have experienced.

By Monday an estimated 88,000 people lost their jobs in the hospitality industry alone and tried to file for unemployment. The system crashed under the demand.

Black Monday brought waves upon waves of frightening news (record job losses, NRL season over, Olympics wont go ahead, Queensland to shut borders, 3,000 Australians stranded on cruise ships; pubs, cafe, licensed premises, gyms etc all shut at midday). There were heartbreaking sights: the streets all across the country empty, except for thousands and thousands of people queuing at a mandated social distance for Centrelink. The next day people started lining up at 4:30am.

The virus is invisible but the economic devastation is a tragedy you could see. Each job loss represents a seismic explosion in an individuals world. By the end of Monday at least 15% of people I know had lost a substantial portion of their income, or their jobs or businesses they had spent decades building up.

And in all this - when you need it most you cannot get a hug from your friends

Suddenly jobless in my circle were yoga teachers, barmen, baristas, cafe owners, a university support worker, university cleaner, personal trainers, roadies, two tour managers for bands, freelance journalists, friends in PR and regional journalism, playwrights, coffee cart owners, sound engineers, winery owners, chefs, cinema operators, kitchen hands, film production crew, ushers at theatres, stage hands, driving instructors, those doing contract work for financial services, event organisers, florists and professional MCs.

When I spoke to these friends, the conversations were flooded with fear.

As a society, white Australia has not experienced this level of fear collectively before.

Fear is everywhere this week. You can see it in peoples eyes and hear it in their voices. It even leeches out of text messages as if the virus had the power to distort even the most disembodied form of communication.

But mostly fear is in the air thick and heavy all around us like an invisible pea soup, carrying an almost chemical taint. This taint feels hormone-like in its elements, a kind of an anti-pheromone that repels rather than attracts. Passing people quickly on the streets the fear is dense and hard to move though and when home, secure in our houses, we carry it back with us on our clothes and around our bodies.

There is cruelty heaped upon cruelty with this pandemic. The fear is not just the mortal fear of contracting what could be a deadly virus, the fear is losing your job and having no money, the fear is being evicted and made homeless, the fear is foreclosure, the fear is being separated from your family whether interstate or overseas (or in my case, a town two hours away), the fear is bankruptcy and sacking your staff, the fear is your debt, the fear is for the education and anxiety of your children, the fear is for the health of your elderly parents, the fear is for your immunocompromised friends. It goes on.

The fear also includes each persons unique personal reckoning. Right now were all meeting our own fears and limits. Character is being swiftly revealed. Each persons bundle of fear is different: you are in an imperfect or dysfunctional relationship, or you are isolated alone in an enormous tower in the city in a 50 sqm flat, or you are single and lonely and miss your friends, or you are sheltering with a violent or unpredictable partner, or you are overwhelmed by your children, or you are in substandard or insecure housing, or you are with near strangers in your random share house, or with your boyfriend of three weeks, whom you really dont know that well yet.

And in all this, when you need it most you cannot get a hug from your friends.

What parts of ourselves are we going to meet there in our quarantine houses and apartments, during our 4am insomnia and aching with loneliness and heartache for the lovely, bright lost world outside our doors?

On Monday, in central Victoria, it was the last day of trade for many small, independent businesses in my town. The high street had changed overnight. A man (security? management?) stood at the door of the butchers shop in gloves, wiping down doors, policing social distancing. Shoppers were wearing face masks, people swerved away from each other when passing in the street. Everything looked familiar, and entirely strange. The weather was crisp and sunny and the gold leaves were yet to turn.

I got my last coffee from my favourite cafe and stood in a warming patch of autumnal sun.

Across the street there was a funeral home, and a service was coming out. There were plastic chairs spaced far apart in the forecourt and large bottles of hand sanitiser on trestle tables.

People came out dispersing onto the street. I watched and waited then I saw it people hesitating, then hugging each other quickly on the road.

Watching this broke my heart. It was a bit of the old world of touch and comfort and a bit of the new world of fear and distance. This is the week were crossing over.

The cafe shut indefinitely now, the tables were packed away. I stood still in the patch of sun for a long time after, crying outside a funeral for a stranger, and then walked home to isolate.

Brigid Delaney is a Guardian Australia columnist

Read the original here:
We crossed over this week: coronavirus is heaping cruelty upon cruelty - The Guardian

I watched Love is Blind with my eyes closed, and I cant say I was surprised.

After days of hearing all about Netflixs new hot dating show, I decided to see what the hype was about, and given the unique circumstances presented in the program experiment, I decided to play along. If the dating was going to be blind, I would be blind too. But it turns out, love really probably isnt all that blind. Theres a lot one can still gather from the sound of anothers voice.

For those unfamiliar, the rules are simple. Participants had about ten days in pods to shop around for a fiance before they must decide whether to get married in a matter of just a few short weeks following a brief getaway to Mexico together. But heres the catch: singles were barred from actually seeing each other until a marriage proposal was accepted in the pod.

With nothing to go off in the way of their appearance except for their voice, which, as I discovered, you can still tell a lot from, it presented a daunting experiment to those participating. Is love really blind? Can couples really disconnect emotional compatibility with physical attraction? Do we really have dating reversed in the real world? Intriguing questions to be sure, but they were presented in a limited experiment at best.

For one, the cast of characters turned out to be pretty predictable. I only kept my eyes shut for the first episode, and by the time episode two rolled around, Cameron and Lauren had already gotten engaged. Both quirky, cute, geeky and charming, it came as little surprise. These traits and mannerisms could be picked up on just by the sounds and inflection in each of their voices, and Lauren had given away that she was black by telling off another guy who speculated about her race.

The other couples in the season were even more predictable, particularly Barnett who was found stuck between Amber and Jessica. Sure its judgmental and assuming, but its human, and all three sounded just as attractive as they looked, and the participants could probably pick up on the others level of attractiveness through the pod. It was no surprise either that Mark, a fitness instructor, was hitting things off with Jessica too, whose high-pitched feminine voice painted a relatively accurate picture as one of the shows prettiest people.

In the end, the couples to end up engaged in Mexico had found their partner evenly matched in their level of attractiveness despite not even seeing each other before they got engaged. Subconsciously, I suspect deep down that they all saw what I did in the blindness of the pods, imagining the figure behind the wall through the context presented by the sounds of their voice and any other clues in their background, i.e., fitness expert. After all, its human nature.

The biggest surprise to come when opening my eyes for the rest of the series was how well the singles so often dressed as if they were preparing for a magazine photoshoot. These people were talking to a wall and drinking copious amounts of alcohol, so why dress up? They were on TV to be fair, but there was plenty of time to play dress up in the more momentous occasions on the show such as the second proposals where their looks were revealed and their trips to Mexico.

The experiment seemed to work, for some couples. Of course thats something to celebrate, and I wish them all the best. But the experiment remained limited in scope as the couples no doubt were able to sense identifiable physical characteristics through the sound of the others voice.

So is love blind? Probably not.

The rest is here:
I Watched 'Love Is Blind' With My Eyes Closed - The Federalist

The CW shared spring premiere dates, which sees season two of In the Dark debut April 16 and DCs Stargirl premiere May 19.

Perry Mattfeld stars in In the Dark. She plays Murphy, a messy 20-something who struggles with love, alcohol and blindness. CBS Television Studios and Warner Bros. Television, in association with Red Hour Films, produce the show. Executive producers are Corinne Kingsbury, Ben Stiller, Jackie Cohn, Nicholas Weinstock, Michael Showalter and Emily Fox .

DCs Stargirl follows high school student Courtney Whitmore as she inspires an unlikely group of heroes to stop the villains of the past. Brec Bassinger, Luke Wilson and Amy Smart star. That show debuts a day after its digital debut on DC Universe.

Geoff Johns executive produces with Melissa Carter, who is co-showrunner, and Greg Berlanti, Sarah Schechter and Greg Beeman. Berlanti Productions and Mad Ghost Productions produce the series in association with Warner Bros. Television.

Go here to see the original:
The CW Shares Start Dates for In the Dark and DCs Stargirl - Broadcasting & Cable

It is with great sadness to announce that Beverly Patte Szewczyk of Rochester (Penfield), NY, passed away peacefully on March 20, 2020, at the age of 78.

Bev was born in Holyoke, MA. She spent her childhood in Dryden, NY and graduated from Ithaca College with a degree in Physical Education. She spent her child-raising years in Rochester (Brighton), NY and Madison, CT. Bev loved the outdoors, sports, and was involved in many PTA activities. She passed these passions on to her children and grandchildren.

Bev was an amazing woman who was an inspiration to anyone who knew her. Even with her blindness, she always had a positive outlook on life. She was a fun-loving spirit and had a recognizable laugh that brightened up any room. Her incredible strength was very evident during her battle to survive numerous medical issues over that last several months. She lived a fantastic life.

Bev is survived by her loving husband of 53 years, Richard Szewczyk; her son, Todd Szewczyk and wife Kim (Hollis, NH); and her daughter, Kathleen Kenney and husband Dan (Jamison, PA). She is also survived by 5 grandchildren, Lindsey, Kyle and Brian Szewczyk and Kylie and Danny Kenney; her brother, George Patte and wife Mary; and sister, Mary Ann Hester and husband Gerry. She is predeceased by her parents, George and Patricia Patte; and her, sister Kathy Malison.

A memorial service and celebration of life will be postponed and announced at a later date due to the virus pandemic that has affected the entire nation. Lansing Funeral Home in Lansing, NY, is assisting the family. In lieu of flowers, please consider a contribution in Bevs name to ABVI (Association for the Blind and Visually Impaired), 500 South Clinton Street, Rochester, NY 14520.

To share a memory, please visit http://www.lansingfuneralhome.com.

See the original post:
Obituary: Beverly Patte Szewczyk - The Ithaca Voice

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Visit link:
Regenerative Medicine Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025 - Daily Science

FAYETTEVILLE, N.C., March 26, 2020 /PRNewswire/ -- Cyto CBD, the CBD company that created precision medical dosing, is partnering with Cumberland Medical Associates and Purple Lotus Aesthetics to help transition patients from opioid-focused treatments to Cannabidiol (CBD) for chronic pain management.

A highly anticipated study, published in January 2020, in Postgraduate Medicine Journal showed that 53% of chronic pain patients that were on opioids for over a year at least were able to reduce their opioid usage and/or completely discontinue opioids with daily supplementation of CBD in just eight weeks. This is why Dr. Sanjiv Dalvi and his wife, Dr. Sumedha Dalvi, who are both certified Addiction and Regenerative Medicine Specialists, started integrating Cyto CBD into their practice at Cumberland Medical.

"The potential benefits of CBD are undeniable, as we are seeing more and more data to support its use in our chronic pain patients. Additionally, given the holistic nature of the product, we are seeing an improvement in overall quality of life, as patients are getting better sleep and experiencing lower stress levels," said Dr. Sanjiv Dalvi, MD, PhD. "We use Cyto CBD because it is a medical grade product with research to confirm its quality. The company owns the entire production chain, including the farm where the hemp is cultivated, and their pharmaceutical approach to quality gives us confidence in recommending it and using it with our patients."

Cumberland Medical focuses on holistic health, pain management, mental health and sleep medicine. The clinic now serves as a hub where patients can access Cyto CBD products through their team of specialists and/or by purchasing the products in office, for personal use.

"With all of the attention that CBD is getting, it is important to remember that this is a product that is ultimately being ingested or applied to our bodies. That is why CBD products should be no less than medical grade and the reason Cyto CBD is manufactured at facilities that are cGMP certified and fully registered with the FDA," said Dr. Cohin Kakar, Chief Marketing Officer of Cyto CBD. "We are thrilled to bring an alternative therapy to the community in North Carolina that we can confidently endorse as safe with high purity."

Cyto CBD is now available at Cumberland Medical and will be available at their upcoming partner practice, Purple Lotus Aesthetics, scheduled to open in the summer of 2020. To schedule an appointment or learn more, please contact Cumberland Medical at (910) 864-0689 or visit their practice located at 5085 Morganton Road, Suite 100, Fayetteville, NC 28314.

About Cyto CBD Headquartered in Los Angeles, California and part of The Anthos Group, Cyto CBD is exclusively available at clinics and pharmacies that focus on health and medical care. Cyto CBD has pharmacists and physicians on staff, endorsements from physicians all over the world, and they serve on the National Cannabis Industry Association (NCIA) Board. Cyto CBD also won the Global Health & Pharma Award for Most Innovative CBD Company in 2019. Cyto CBD is an educator in the industry, as the team hosts regular educational webinars, keeping the medical community updated and informed around new science in CBD and cannabinoids.

For more on Cyto CBD visit cytocbd.com, and follow on Facebook, Twitter, Instagram.

Go here to see the original:
Cumberland Medical & Purple Lotus Aesthetics Partner With Cyto CBD To Address Opioid Epidemic In North Carolina - The Mountaineer

By A. Rahman Ford, PNN Columnist

No group is more worthy of the revolutionary benefits of stem cell therapy than Americas military veterans. While the U.S. Department of Veterans Affairs (VA) thinks the field is in its infancy and much more research is needed before stem cells are offered as treatment, brave practitioners are stepping forward to help veterans NOW.

Dr. Joseph Kanan and his staff at the Tullahoma Chiropractic Center are providing free stem cell therapy for veterans who suffer from chronic pain. Kanan in partnership with Veterans in Pain recently performed his first pro bono procedure on a veteran named Ryan, who has severe hip pain. Stem cell injections into Ryans hip, which are not covered by insurance, normally would have cost $6,500. Ryan got them for free.

I think veterans do a lot for our country and there are very few doctors that are performing medical procedures like this, Kanan told The Tullahoma News. We were very glad to be able to do this for him.

Kanan says his Tennessee clinic performs stem cell therapy for veterans twice a month and has had good results so far. One patient was able to avoid a knee replacement and reported consistent improvement one year after the procedure. Patients can expect to experience 10 percent improvement every month for 10 months.

Veterans in Pain is a non-profit that connects military veterans with civilian physicians who provide free regenerative medicine treatments for chronic pain. VIP has provided $250,000 worth of services since 2019.

VIP founder and president Micaela Bensko is herself a stem cell therapy recipient. She spent years in a wheelchair after an accident in her driveway left her with severe spine damage that led to arachnoiditis, a chronic inflammation of spinal nerves. A friend suggested stem cell therapy, which inspired Bensko to establish VIP as a resource for veterans.

Veterans in Pain connects each veteran with a volunteer physician in their area. If one cannot be located, the cost of transportation and accommodations are covered for treatments, as they were for Ryan. Veterans associated with VIP visit schools, organizations and corporations sharing their story of recovery. Most of VIPs funding is provided by small individual donations, grants and grassroots fundraising.

According to the National Institutes of Health, nearly two-thirds of veterans report having chronic pain, with about 9% having severe pain. Chronic pain among veterans is closely associated with mental health conditions such as depression, anxiety, poor sleep and substance abuse disorders. Many veterans suffer from more than one condition.

Because of red tape and a shortage of pain management specialists at the VA, many veterans suffering from chronic pain are left devoid of proper diagnosis and treatment, causing many to self-medicate or search for answers on their own.Chronic pain can lead to substance abuse, a common and growing trend among veterans. A 2017 study found that 30% of military suicides were preceded by alcohol or drug abuse.

The dire plight of military veterans suffering from chronic pain is yet another compelling reason for the FDA to loosen its regulation of stem cell therapy. Our heroes are counting on it.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.

See the original post here:
Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network

Yewei Jia,1,* Wei He,1,* Hanxiao Zhang,2 Lei He,1 Yanben Wang,1 Tan Zhang,1 Jiaxuan Peng,3 Peng Sun,2 Yu Qian1

1Department of Orthopaedics, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, Peoples Republic of China; 2The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, Peoples Republic of China; 3Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi 530021, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yu QianDepartment of Orthopaedics, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, Peoples Republic of ChinaTel +86 13905754033Email doctor120@hotmail.com

Purpose: Osteoarthritis (OA) is one of the most common degenerative joint diseases in the world, characterized primarily by the progressive degradation of articular cartilage. Accumulating evidence has shown that Morusin, a flavonoid derived from the root bark of Morus alba (mulberry) plants, exerts unique protective properties in several diseases. However, its effects on OA, specifically, have not yet been characterized.Methods: In this study, we evaluated the anti-inflammatory effect of Morusin on mouse chondrocytes and its underlying mechanism in vitro. In addition, the protective effect of Morusin on destabilization of the medial meniscus (DMM) model was also explored in vivo.Results: In vitro, IL-1-induced activation of inflammatory factors (TNF-, IL-6, INOS and COX2) was dramatically suppressed by Morusin. Further, Morusin treatment inhibited the expression of ADAMTS5 and metalloproteinase (MMPs), both of which regulate extracellular matrix degradation. Morusin also decreased IL-1-induced p65 phosphorylation and IB degradation. In vivo, degradation of the articular cartilage following surgical DMM, which mimicked OA pathology, was abrogated following treatment with Morusin, thus demonstrating a protective effect in the DMM model.Conclusion: Herein, we demonstrate that Morusin reduces the OA inflammatory response in vitro and protects against articular cartilage degradation in vivo potentially via regulation of the NF-B pathway. Hence, Morusin may prove to be an effective candidate for novel OA therapeutic strategies.

Keywords: osteoarthritis, chondrocytes, Morusin, IL-1, NF-B pathway

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Link:
Morusin Ameliorates IL-1-Induced Chondrocyte Inflammation and Os | DDDT - Dove Medical Press

GOLDEN, CO / ACCESSWIRE / March 26, 2020 / Vitro Diagnostics, Inc. (OTC:VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company's gross profit margins improved to 75% up from 73% in the comparative prior year's quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx Stem Cells. The company's clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year's comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company's first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company's revenue lines of Nutra Vivo/STEMulize, AlloRx Stem Cells, private labeled InfiniVive-MD Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

Our partnership with DVC. Stem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Chrohn's disease, Alzheimer's disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Chrohn's disease patient showed significant improvement as did both the AD & COPD patients.

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer's disease.

We have received an initial order of AlloRx Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

Vitro Biopharma's cosmetic topical stem cell serum is being distributed by InfiniVive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was "Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics." This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

http://www.jackzamoramd.com http://www.infinivivemd.com

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients." The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10- years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.President, CEO & Chairman of the Boardwww.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James MusickChief Executive OfficerVitro BioPharma(303) 999-2130 Ext. 3E-mail: jim@vitrobiopharma.comwww.vitrobiopharma.com

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/582759/Vitro-Biopharma-First-Quarter-ended-January-31-2020-Financial-Results-of-Operations

Read the original post:
Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Benzinga

Newswise When smartphones and social media became ubiquitous for students, cyberbullying rates went up. This makes sense, of course, because there was now an almost limitless number of potential targets and aggressors, said Sameer Hinduja, Ph.D., a professor in the School of Criminology and Criminal Justice within FAUs College for Design and Social Inquiry, and co-director of the Cyberbullying Research Center. Well, during this unprecedented time when theyre all stuck at home, those same students will be using apps even more than they already do with them being forced to use online platforms for learning, regardless of their level of comfort or proficiency. Teachers are delivering education not just in learning management systems like Canvas, Blackboard, and Moodle, but even on Roblox, Twitch, and YouTube, among others.

In the midst of major crises where everyone is already on edge, Hinduja says hostility toward others tends to escalate along with self-preserving and self-defensive behaviors. This may manifest even more so between students in their online interactions their posts, comments, pictures and videos. Some of it will be mild, and some of it will be severe. Some of it will be what students are used to and will not bother them, but some of it will be brand new and a jarring, wounding experience. This may be especially true for those who are not used to learning and interacting in online-only spaces (and may also disproportionately affect more vulnerable populations of youth).

Hinduja cautions that many cyberbullying targets will hesitate to get help from their parents. When it happens, they may suffer silently since there will not be any visual cues for educators to see or investigate because the student is not physically at school. In addition, with everyone now receiving instruction online, students cannot readily stop by the guidance counselors office, chat with a teacher after class, or let their coach know about what is troubling them and affecting their ability to play sports (since youth sports also are shut down). Those opportunities for meaningful, connective conversations and check-ins largely will not happen organically.

Its also very possible that xenophobic/racist cyberbullying may go up. Some continue to call COVID-19 a foreign virus and parents have complained that their children are being accused as carriers just because they are Asian, said Hinduja. Im Asian and have dealt with my share of bullying based on race/ethnicity, and so I am particularly sensitive to this issue and simply do not want to see it spiral out of control.

Hinduja provides a number of suggestions for educators:

Students also are going to struggle with feelings of isolation because they are not able to go to school and connect and interact with their peers in person, said Hinduja.

He also suggests that parents need to be creative to make sure that their children do not suffer from extremes of social isolation:

With intentionality, graciousness, and good will, we dont have to just survive through this crisis. We can actually thrive, and our relationships with the youth we care for can be better off than they were before all of this even began, asserts Hinduja.

Additional information and tips can be found at the Cyberbullying Research Center.

- FAU -

About Florida Atlantic University: Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida. FAUs world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAUs existing strengths in research and scholarship. For more information, visit fau.edu.

Read more here:
Another Unintended Consequence of COVID-19: Cyberbullying Could Increase - Newswise

With reliable and impactful research methodologies, Regenerative Medicine Market Research provides critical information pertaining to the growth of the global Regenerative Medicine market. Our team of analysts monitor the ongoing developments within the Regenerative Medicine space and provide an unbiased assessment of the global Regenerative Medicine market. The data included in the report are procured from reliable and trustworthy primary and secondary sources.

According to the findings of the report, the value of the global Regenerative Medicine market in 2018 was ~US$ XX (Mn/Bn) and expected to attain a value of ~US$ XX (Mn/Bn) by the end of 2029. In addition, the report reveals that the global Regenerative Medicine market is likely to grow at a CAGR of XX% during the forecast period (2019-2029).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2042766&source=atm

Some of the leading companies profiled in the market study include:

The presented market study includes a brief introduction of the Regenerative Medicine market to enhance the reading experience of our users. Further, a thorough quantitative and qualitative analysis of each of these segments is provided in the report along with graphs, tables, and figures to support the data.

The following manufacturers are covered in this report:ABS Protection GmbHMammutClarus CorporationBackcountry AccessScottOrtovoxARVAOsprey PacksThe North FaceDakineMystery RanchMillet(Calida Group)MotorfistDeuter

Regenerative Medicine Breakdown Data by TypeMono Avalanche AirbagsDual Avalanche AirbagsRegenerative Medicine Breakdown Data by ApplicationSkiingClimbingHikingOthers

Regenerative Medicine Production by RegionUnited StatesEuropeChinaJapanSouth KoreaIndiaOther Regions

Regenerative Medicine Consumption by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalyRussiaRest of EuropeCentral & South AmericaBrazilRest of South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaRest of Middle East & Africa

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2042766&source=atm

Key information drawn from the Regenerative Medicine market study

The market report aims to address the following queries:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2042766&licType=S&source=atm

Originally posted here:
Regenerative Medicine Market Report 2019: With Essential Analysis of Market, Industry News and Policies by Regions, Top Manufacturers, Types and...

Paul Bisaro and Gail Naughton, Ph.D., Appointed as Independent Directors

On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, Chairman Tommy G. Thompson today announced the appointments of Paul Bisaro and Gail Naughton, Ph.D., to the Companys Board of Directors. The appointments fill two of the vacancies created by the resignations from the Board of Brian Bernick, M.D., John C.K. Milligan, IV and Nicholas Segal. Dr. Bernick will continue to serve as a Co-Founder of TherapeuticsMD on a full-time basis, supporting the Companys outreach with healthcare providers. Mr. Milligan will continue to serve as the President of TherapeuticsMD on a full-time basis, leading the Companys infrastructure and critical operations.

"We are very pleased to add Paul and Gail as the newest independent directors to our Board. Each has a wealth of experience as both directors and members of senior management at successful organizations," said former Governor and Secretary of Health and Human Services, Thompson. "This is an exciting time in our companys growth and development, and we believe that Paul and Gails respective skill sets will complement our recent transformation to a commercial organization."

"On behalf of the TherapeuticsMD Board of Directors, I would like to thank Brian, John and Nick for their service to our company," said Thompson. "Brians passion for innovation and persistence in solving patient needs are the reasons we have world-class products. Brian will continue to serve as our Co-Founder and play a key role in our outreach to healthcare providers. Johns commitment and can-do attitude built the infrastructure and critical operations that our Company has today. John will continue to serve as our President and lead our infrastructure and critical operations. Nick and his family were among our early investors and without their vision and commitment we would not be where we are today. We are excited to welcome Paul and Gail to the TherapeuticsMD Board of Directors. Each of them brings significant experience that we believe will activate our next stage of growth."

"I am very pleased and honored to be joining the TherapeuticsMD Board of Directors," said Mr. Bisaro. "I believe TherapeuticsMDs portfolio of differentiated products meets many of the significant unmet needs facing women today. In addition, I believe the Companys vitaCare platform which was created to remove the hassle and lack of visibility that patients often face when dealing with their insurance coverage, reimbursement and supply is a unique capability that supports TherapeuticsMDs patients. I look forward to working with the Board and management team to use these assets to help our patients while continuing to focus on creating long-term value for our shareholders."

Mr. Bisaro is an accomplished global business leader with more than 25 years of generic and branded pharmaceutical experience, and a track record of driving company growth through operational execution and corporate transformation. He has served as Executive Chairman of Allergan, plc (formerly Actavis, plc), President, Chief Executive Officer and a member of the Board of Directors of Actavis (and its predecessor firm Watson Pharmaceuticals, Inc.), Executive Chairman of Amneal Pharmaceuticals, Inc., and President, Chief Executive Officer and a member of the Board of Directors of Impax Laboratories, Inc. until its acquisition by Amneal. He also served as President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc.

"I am honored and delighted to be joining the Board of Directors of TherapeuticsMD. The directors and executives have created innovative products that are poised to greatly enhance womens health and I share in their vision in continuing to develop solutions that will be transformative to healthcare worldwide," said Dr. Naughton.

Dr. Naughton is an accomplished life sciences executive and researcher. Dr. Naughton founded two regenerative medicine companies and is the holder of more than 105 U.S. and foreign patents. She served as the Dean of the College of Business at San Diego State University from 2002-2011. Her current venture, Histogen, is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions. She currently serves as Histogens Chief Scientific Officer and Chief Business Development Officer and is the inventor of its core technology. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast) and SkinMedicas TNS product for skin care. Dr. Naughton has been extensively published and is a frequent speaker in the field of tissue engineering and regenerative medicine. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering.

Story continues

"We are thankful to each of Brian, John and Nick for their years of service on our Board and look forward to continuing to work with Brian and John as key members of our leadership team," concluded TherapueticsMD Chief Executive Officer Robert G. Finizio. "As TherapeuticsMD looks to the future, adding two seasoned experts in Mr. Bisaro and Dr. Naughton to the Board while continuing to utilize two proven performers in Dr. Bernick and Mr. Milligan, is an ideal scenario."

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit http://www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMDs objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of managements experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the companys control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the companys filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the companys ability to maintain or increase sales of its products; the companys ability to develop and commercialize IMVEXXY, ANNOVERA, BIJUVA and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the companys current or future approved products or preclude the approval of the companys future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the companys ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the companys reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the companys licensees to commercialize and distribute the companys products; the ability of the companys marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the companys products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the companys common stock and the concentration of power in its stock ownership. PDF copies of the companys historical press releases and financial tables can be viewed and downloaded at it website: http://www.therapeuticsmd.com/pressreleases.aspx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005366/en/

Contacts

Investor Contact Nichol OchsnerVice President, Investor Relations561-961-1900, ext. 2088Nochsner@TherapeuticsMD.com

Read more:
TherapeuticsMD Strengthens Board with Appointment of Industry Leaders - Yahoo Finance

The positioning of the Global Cell Culture Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Culture Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872141/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Culture Market including are Becton, Dickinson and Company, Cellgenix, Corning, Danaher, Eppendorf, Fujifilm Irvine Scientific, GE Healthcare, Hi-Media Laboratories, Invivogen, Lonza Group AG, Merck KGaA, Miltenyi Biotec, Promocell, and Sartorius AG.

On the basis of Product, the Global Cell Culture Market is studied across Consumables and Equipment.

On the basis of Application , the Global Cell Culture Market is studied across Biopharmaceutical Production, Diagnostics, Drug Screening and Development, Stem Cell Research, and Tissue Engineering & Regenerative Medicine.

On the basis of End User , the Global Cell Culture Market is studied across Cell Banks, Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Culture Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Culture Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Culture Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Culture Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Culture Market

The report answers questions such as:1. What is the market size of Cell Culture market in the Global?2. What are the factors that affect the growth in the Global Cell Culture Market over the forecast period?3. What is the competitive position in the Global Cell Culture Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Culture Market?5. What are the opportunities in the Global Cell Culture Market?6. What are the modes of entering the Global Cell Culture Market?Read the full report: https://www.reportlinker.com/p05872141/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Originally posted here:
The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual...